Hypoxia induces dilated cardiomyopathy in the chick embryo:mechanism, intervention, and long-term consequences by Tintu, Andrei et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypoxia induces dilated cardiomyopathy in the chick embryo
Citation for published version:
Tintu, A, Rouwet, E, Verlohren, S, Brinkmann, J, Ahmad, S, Crispi, F, van Bilsen, M, Carmeliet, P, Staff, AC,
Tjwa, M, Cetin, I, Gratacos, E, Hernandez-Andrade, E, Hofstra, L, Jacobs, M, Lamers, WH, Morano, I,
Safak, E, Ahmed, A & le Noble, F 2009, 'Hypoxia induces dilated cardiomyopathy in the chick embryo:
mechanism, intervention, and long-term consequences' PLoS One, vol 4, no. 4, pp. e5155. DOI:
10.1371/journal.pone.0005155
Digital Object Identifier (DOI):
10.1371/journal.pone.0005155
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLoS One
Publisher Rights Statement:
Copyright: © 2009 Tintu et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Hypoxia Induces Dilated Cardiomyopathy in the Chick
Embryo: Mechanism, Intervention, and Long-Term
Consequences
Andrei Tintu1,2., Ellen Rouwet3., Stefan Verlohren1,4., Joep Brinkmann1., Shakil Ahmad5, Fatima
Crispi6, Marc van Bilsen7, Peter Carmeliet8, Anne Cathrine Staff9, Marc Tjwa10, Irene Cetin11, Eduard
Gratacos6, Edgar Hernandez-Andrade6, Leo Hofstra12, Michael Jacobs2, Wouter H. Lamers13, Ingo
Morano14, Erdal Safak15, Asif Ahmed5, Ferdinand le Noble1*
1 Laboratory for Angiogenesis and Cardiovascular Pathology, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany, 2Department of Surgery, Cardiovascular
Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands, 3Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the
Netherlands, 4Department of Obstetrics, Charite´ University Medicine, Berlin, Germany, 5Department of Reproductive & Vascular Biology, Centre for Cardiovascular
Sciences, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom, 6Department of Maternal-Fetal Medicine, Hospital Clinic, University
of Barcelona, Barcelona, Spain, 7Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands, 8Center of
Transgene Technology and Gene Therapy, University of Leuven, Leuven, Belgium, 9Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway,
10 Institute of Cardiovascular Regeneration, Centre for Molecular Medicine, University of Frankfurt, Frankfurt, Germany, 11 Institute of Obstetrics and Gynecology, IRCCS
Foundation Policlinico, Mangiagalli & Regina Elena, University of Milan, Milan, Italy, 12Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht
University, Maastricht, the Netherlands, 13Department of Embryology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, Maastricht, the
Netherlands, 14 Research Group Molecular Muscle Physiology, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany, 15Department of Cardiology, Franz
Volhard Clinic, Helios Clinic Berlin-Buch, Charite´ University, Berlin, Germany
Abstract
Background: Intrauterine growth restriction is associated with an increased future risk for developing cardiovascular
diseases. Hypoxia in utero is a common clinical cause of fetal growth restriction. We have previously shown that chronic
hypoxia alters cardiovascular development in chick embryos. The aim of this study was to further characterize cardiac
disease in hypoxic chick embryos.
Methods: Chick embryos were exposed to hypoxia and cardiac structure was examined by histological methods one day
prior to hatching (E20) and at adulthood. Cardiac function was assessed in vivo by echocardiography and ex vivo by
contractility measurements in isolated heart muscle bundles and isolated cardiomyocytes. Chick embryos were exposed to
vascular endothelial growth factor (VEGF) and its scavenger soluble VEGF receptor-1 (sFlt-1) to investigate the potential role
of this hypoxia-regulated cytokine.
Principal Findings: Growth restricted hypoxic chick embryos showed cardiomyopathy as evidenced by left ventricular (LV)
dilatation, reduced ventricular wall mass and increased apoptosis. Hypoxic hearts displayed pump dysfunction with
decreased LV ejection fractions, accompanied by signs of diastolic dysfunction. Cardiomyopathy caused by hypoxia
persisted into adulthood. Hypoxic embryonic hearts showed increases in VEGF expression. Systemic administration of
rhVEGF165 to normoxic chick embryos resulted in LV dilatation and a dose-dependent loss of LV wall mass. Lowering VEGF
levels in hypoxic embryonic chick hearts by systemic administration of sFlt-1 yielded an almost complete normalization of
the phenotype.
Conclusions/Significance: Our data show that hypoxia causes a decreased cardiac performance and cardiomyopathy in
chick embryos, involving a significant VEGF-mediated component. This cardiomyopathy persists into adulthood.
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Introduction
Epidemiological studies have shown that intrauterine stress,
reflected by intrauterine growth restriction and low birth weight,
increases the risk of developing cardiovascular diseases later in life
[1–5]. The mechanisms underlying the relation between growth
restriction and cardiovascular disease are unknown. A common
cause of fetal growth restriction in clinical practice is intrauterine
hypoxia due to uteroplacental insufficiency [6,7].
In experimental models of embryonic hypoxia, it has been
found that chronic hypoxia results in growth restriction, aortic
remodeling, sympathetic hyperinnervation, and left ventricular
(LV) pump dysfunction in the embryo [8–10]. The aim of the
present study was to further characterize the effects of embryonic
hypoxia on cardiac structure and function. In addition, we
investigated the potential role of vascular endothelial growth factor
(VEGF) herein. VEGF is a hypoxia-regulated cytokine that plays a
pivotal role in angiogenesis, neurogenesis, and cardiac morpho-
genesis [11–13]. Studies in mice have indicated that even small
perturbations in VEGF levels affect cardiovascular development
and embryo survival [14–16].
We report that chronic hypoxia in chick embryos resulted in LV
dilatation and several other structural and functional hallmarks of
cardiomyopathy. Left ventricular dilatation and signs of cardio-
myopathy persisted into adulthood and were, at least partly,
secondary to increased VEGF levels.
Results
Hypoxia induces LV dilatation, cardiomyocyte apoptosis
and signs of cardiomyopathy in E20 embryonic chick
hearts
Chick embryos that had been exposed to 15% O2 throughout
embryonic development displayed lower arterial blood PO2 levels,
elevated hematocrit, and lower total body, liver and heart weights
as described previously [9,10]. Hearts of hypoxic embryos
displayed LV dilatation and loss of ventricular wall mass, without
congenital cardiac defects (Figure 1A–E). Hearts of hypoxic chick
embryos contained an increased number of apoptotic cardiomy-
ocytes (Figure 1F–G) and histological analysis revealed disturbed
arrangement of cardiomyocytes (Figure 1H–I). Cardiomyocyte
degeneration, myofibrillar disarray with disruption of sarcomeric
architecture, leaky blood vessels, and infiltration of inflammatory
cells were observed at the ultrastructural level (Figure 1J–O).
Hearts of hypoxic chick embryos also contained increased levels of
glycogen (Figure 1P–Q), and expression levels of atrial natriuretic
factor (ANF) were increased by a factor 2 (Figure 1R). Collagen
content showed a 40% increase (Figure 2A–C), reflecting
enhanced fibrosis. Levels of the sarcomeric proteins titin
(Figure 2D–E) and myosin heavy chain (MHC, Table 1) were
lowered in hypoxic embryonic chick hearts. The titin-to-MHC
ratio was similar in normoxic and hypoxic hearts. Although the
hypoxia-induced decrease in total titin content involved both the
N2BA and the N2B isoform, the ratio between the isoforms
changed significantly (Figure 2F, Table 1).
Hypoxia reduces cardiac performance in E20 chick
embryos
Assessing cardiac function in vivo by echocardiography revealed
reduced LV ejection fractions and confirmed the presence of LV
dilatation in hypoxic embryos (Figure 3A–D). Cardiac contractility
was analyzed in isolated LV muscle bundles. The capacity to
increase contractile force in response to stretch was significantly
lower at 100% Lmax in LV muscle bundles isolated from hypoxic
hearts (Figure 4A). This indicates that the Frank-Starling
mechanism is impaired. The calcium-mediated increase in
contractile force development was approximately 40% lower in
LV muscle bundles from the hypoxic embryos (Figure 4B). Passive
tension, as determined by diastolic force during stretching, was
significantly higher in hypoxic LV muscle bundles (Figure 4C).
The time to 50% relaxation at varying calcium concentrations was
significantly prolonged in the hypoxic group (Figure 4D).
Cardiomyopathy caused by embryonic hypoxia persists
in adult animals
Adult chickens that had been exposed to hypoxia during
embryonic development displayed severe LV dilatation in later life
(Figure 5A, B). LV cavity cross-sectional area was approximately
4-fold larger than that of adult hearts prenatally exposed to
normoxia (18.661.3 mm2 versus 4.660.6 mm2; n=7; P,0.05).
LV dilatation was accompanied by increases in myocardial
collagen content (Figure 5C–E). Both the contractile responses
and relaxation times to increasing calcium concentrations were
significantly impaired in isolated LV muscle bundles from chickens
prenatally exposed to hypoxia (Figure 5F–G).
VEGF affects the contractility of isolated LV muscle
bundles and cardiomyocytes
Hypoxic chick embryos showed an increased cardiac expression
of the large VEGF-A isoforms VEGF166 and VEGF190 at both
E13 and E20 (Figure 6A). To explore the potential role of VEGF
as a mediator of cardiac dysfunction, we first tested the effects of
different VEGF-A isoforms on LV muscle bundles and isolated
cardiomyocytes. In LV muscle bundles from normoxic chick
embryos, incubation with the rhVEGF165 isoform induced a
severe reduction of the contractile reserve (Figure 6B). Neither
rhVEGF121, the human equivalent of the smaller VEGF122
isoform that did not show increased expression in our model
(Figure 6A), nor placental growth factor (rhPlGF-1), a second
growth factor belonging to the VEGF protein family, exerted this
effect (Figure 6B). Analogously, administration of rhVEGF165 to
isolated cardiomyocytes caused a decrease in fractional shortening
(Figure 6C), whereas rhPLGF-1 did not exert any effects (data not
shown). The VEGF receptors VEGFR-2 and neuropilin-1 (NRP1)
were demonstrated in isolated cardiomyocytes (Figure 6D). The
negative inotropic effect of VEGF165 was abolished when muscle
bundles were co-incubated with rhVEGF165 and sFlt-1 or with the
VEGFR-2 tyrosine kinase inhibitor SU5416 [17] (Figure 6B). The
used VEGF isoforms exhibit differential affinity to VEGFR-1,
VEGFR-2 and the VEGF165 co-receptor NRP1. Since only
VEGF165, but not VEGF121 or PlGF-1, binds to NRP1, we next
investigated the potential role of NRP1 using the NRP1 ligand
Semaphorin-3A (Sema3A). To achieve competitive antagonism of
VEGF165 binding to NRP1, muscle bundles were co-incubated
with Sema3A [18], which prevented the negative inotropic effect
of VEGF165 (Figure 6B).
VEGF is a mediator of cardiomypathy in the hypoxic chick
embryo
We next examined whether VEGF could induce cardiomyop-
athy in vivo. rhVEGF165 was systemically administered to normoxic
chick embryos between E10 and E19. This resulted in LV
dilatation and a dose-dependent loss of ventricular wall mass
(Figure 6E–H). We tested whether lowering functional VEGF
levels in hypoxic embryos influenced the development of
cardiomyopathy in our model. The VEGF scavenger sFlt-1 was
systemically administered to hypoxic embryos from E10 to E19.
Fetal Hypoxia & Cardiomyopathy
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The increase in LV lumen diameter and loss of LV wall mass as
observed in hypoxic embryos at E20 was thereby almost
completely prevented (Figure 7A–E). Hearts from hypoxic
embryos exposed to sFlt-1 were macroscopically indistinguishable
from normoxic embryos and their LV ejection fraction, as assessed
by echocardiography, was normalized (Figure 7F). Administration
Figure 1. Histology of E20 chick embryo hearts. A to D, LV dilatation in hypoxic hearts. Scale bars represent 1 mm. E, cardiac morphometry
showing a larger LV lumen and a thinner LV wall in hypoxia. F and G, increased number of apoptotic cardiomyocytes (arrowheads) in hypoxic hearts.
Scale bars represent 100 mm. H and I, HE staining showing increased intracellular spaces (arrows) in the hypoxic hearts. J to O, ultrastructural analysis
showing myofibrillar disarray, disruption of sarcomeric architecture (L and M, red circles), endothelial gaps in capillaries (N, arrowheads; L = lumen)
and infiltration of inflammatory cells (O, asterisk) in hypoxic hearts. P and Q, PAS staining demonstrating increased glycogen deposition (red) in
hypoxic hearts. R, Q-PCR showing increased ANF expression in hypoxic hearts. Data are shown as mean6SE; * P,0.05 Hypoxia versus Normoxia.
doi:10.1371/journal.pone.0005155.g001
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of sFlt-1 also restored contractility of isolated LV muscle bundles
in E20 hypoxic embryos, to levels equaling the contractile
responses to calcium of normoxic muscle bundles (Figure 7G).
The time to 50% relaxation, however, was not influenced by sFlt-1
exposure, and remained at the level of hypoxic muscle bundles
(Figure 7H).
Discussion
Fetal hypoxia is a common clinical problem, frequently caused by
uteroplacental insufficiency and disturbed blood supply to the fetus.
Several studies have shown that hypoxia has significant impact on the
developing heart in early developmental stages [8–10,19–21]. Here,
we demonstrated that embryonic hypoxia results in cardiac disease at
both late embryonic stages and adulthood in a chick model.
Furthermore, we identified a putative role for elevated cardiac
VEGF165 levels in the etiology of hypoxia-initiated cardiac disease.
Hypoxic chick embryos displayed severe LV dilatation just prior
to hatching, which was accompanied by a reduced LV wall mass,
increased apoptosis, as well as a lowered cardiac content of the
sarcomeric proteins MHC and titin. At the molecular level, we
found increases in glycogen accumulation, gene induction of ANF
and increased collagen contents, which are all linked to the
development of cardiac hypertrophy and failure [22]. Our data
suggest that the hypoxia-induced LV dilatation is associated with a
loss of cardiomyocytes. This loss was estimated to amount
approximately 9%, as evaluated by quantifying cells on tissue
sections (data not shown).
Figure 2. Cardiac content evaluation of E20 chick embryo hearts. A to C, trichrome Masson staining of left ventricular myocardium of E20
chick embryos showing increased interstitial collagen deposition in hypoxic hearts, both n= 6. Arrows denote collagen (blue). Scale bars represent
100 mm. Collagen content is significantly higher in hypoxic hearts (C). D, gel electrophoresis and densitometric analysis showing lowered titin protein
levels and its isoforms in hypoxic E20 chick embryo hearts. E, densitometric quantification of total titin composition (N2BA+N2B) showing decreased
levels of total titin in the hearts of the hypoxic chick embryos, n = 7 in both groups. F, the N2BA-to-N2B expression ratio is decreased in hypoxic
embryonic hearts. N2BA: the large more compliant isoform (3300 kDa) of titin, N2B: the smaller stiffer isoform (3000 kDa) of titin, nebulin (800 kDa).
Data are shown as mean6SE; * P,0.05, ** P,0.01 Hypoxia versus Normoxia; a.u. arbitrary units. (note: panel D does not show a molecular weight
marker, because no suitable markers for the large molecular weight of titin are available).
doi:10.1371/journal.pone.0005155.g002
Table 1. Expression of total titin, titin isoforms, titin isoforms/
total titin ratios and titin/myosin ratios.
Normoxia (n=7) Hypoxia (n =7)
Total Titin (a.u.) 58.463.2 41.464.2 *
N2BA (a.u.) 32.861.8 21.962.9 **
N2B (a.u.) 25.561.4 19.561.5 *
Myosin (a.u.) 115.362.4 10061.8 **
N2BA/Total Titin (%) 56.260.5 51.961.9 *
N2B/Total Titin (%) 43.860.5 48.161.9 *
N2BA/N2B (%) 128.662.5 110.268.8 *
N2B/N2BA (%) 77.961.4 94.066.9 *
Total Titin/Myosin (%) 50.662.5 40.963.6
a.u.: arbitrary units.
*P,0.05.
**P,0.01.
doi:10.1371/journal.pone.0005155.t001
Fetal Hypoxia & Cardiomyopathy
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Cardiac function upon chronic hypoxia was severely compro-
mised in our chick embryo model. Systolic dysfunction was
evidenced by a reduced LV ejection fraction in echocardiography
and by significant decreases in contractile force development in
LV muscle bundles isolated from hypoxic hearts. Moreover, we
previously demonstrated cardiac dysfunction in an isolated heart
Figure 3. Echocardiography in E20 chick embryos. A and B, M-mode echo of normoxic and hypoxic embryos showing diastolic LV dilatation
(arrows). C, diastolic left ventricular diameter is larger in the hypoxic embryos. D, hypoxic embryos demonstrate lower ejection fraction. Data are
shown as mean6SE; * P,0.05 Hypoxia versus Normoxia.
doi:10.1371/journal.pone.0005155.g003
Figure 4. Contractile properties of LV muscle bundles in E20 chick embryos. A, the length-active tension relationship of LV muscle bundles
is depressed in hypoxic E20 chick embryo hearts. B, LV contractility was lower in hypoxic LV muscle bundles. C, passive tension during stretching of
LV muscle bundles is higher in hypoxic hearts, n = 6 and n= 8, respectively. D, the time to 50% relaxation is significantly prolonged in hypoxic as
compared with normoxic hearts, both in response to increasing calcium concentrations, both n= 9. Data are shown as mean6SE; * P,0.05, ** P,0.01
Hypoxia versus Normoxia.
doi:10.1371/journal.pone.0005155.g004
Fetal Hypoxia & Cardiomyopathy
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perfusion system [9]. Additionally, muscle bundles from hypoxic
hearts displayed an increase in passive tension upon stretching
together with an increase in the time to 50% relaxation, indicating
that impaired contractility was accompanied by increases in
myocardial stiffness. Impaired left ventricular relaxation and
reduced compliance are well known characteristics of cardiac
diastolic dysfunction [23], and may be caused by abnormalities in
the extracellular matrix or in the contractile apparatus of
cardiomyocytes [24,25]. The increase in the interstitial protein
collagen and decrease in the sarcomeric proteins MHC and titin in
hypoxic hearts might account for the observed changes [26–29].
We also found reduced titin N2BA-to-N2B expression ratios in
hypoxic chick hearts. The shift in expression ratio of N2BA (the
larger, more compliant isoform) towards N2B (the smaller, stiffer
isoform) in the dilated hypoxic hearts will likely increase
myocardial stiffness and impair cardiac compliance [30,31].
Interestingly, adult chickens exposed to chronic hypoxia during
embryonic development showed severely dilated hearts and
impairment in the contractility of isolated LV muscle bundles. This
strongly suggests that the embryonic hypoxia-induced contractile
dysfunction is permanent. Moreover, the adult hearts displayed
increased cardiac collagen contents and prolonged muscle bundle
relaxation times, suggesting that the biomechanical alterations
induced by embryonic hypoxia also persist into adulthood.
Figure 5. Hypoxia-induced dilated cardiomyopathy persists in adult chickens. A and B, morphology of adult hearts showing LV dilatation
in adult chickens prenatally exposed to hypoxia (P-H) compared with adult chickens prenatally exposed to normoxia (P-N). C to E, trichrome Masson
staining of left ventricular myocardium of adult chickens showing increased interstitial collagen deposition in hearts from adult animals prenatally
exposed to hypoxia, both n= 6. Collagen content is significantly higher in hypoxic hearts (E). F, generated LV contractility was lower in muscle
bundles from P-H animals. G, relaxation properties of LV muscle bundles isolated from adult chicken hearts. The time to 50% relaxation in response to
increasing calcium concentrations is significantly prolonged in P-H animals, n = 7 in each group. Data are shown as mean6SE; * P,0.05, ** P,0.01 P-
H versus P-N.
doi:10.1371/journal.pone.0005155.g005
Fetal Hypoxia & Cardiomyopathy
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Figure 6. Influence of VEGF165 on the function and structure of the embryonic heart. A, PCR showing increased expression of VEGF166 and
VEGF190 isoforms in the hypoxic heart at E13 and E20. B, contractile reserve of LV muscle bundles from normoxic E20 hearts after ex vivo incubation
with VEGF165 (n = 6), VEGF121 (n = 7), PlGF-1 (n = 6), VEGF165+sFlt-1 (n = 6), VEGF165+SU5416 (n = 7), and VEGF165+Sema3A (n = 7). Only VEGF165 exerts a
negative inotropic effect compared to vehicle (n = 13), which is abolished when co-incubated with sFlt-1, the VEGFR-2 inhibitor SU5416, or the NRP1
ligand Sema3A. C, VEGF165 impairs fractional shortening of isolated cardiomyocytes (n = 15). D, Q-PCR showing expression of VEGF-A, VEGFR-2, and
NRP1 in isolated cardiomyocytes. E to H, in vivo treatment of normoxic embryos with VEGF165 leads to dose dependent LV dilatation. Data are shown
as mean6SE; * P,0.05 VEGF165 versus vehicle in vivo incubated E20 normoxic chick embryos. ** P,0.01 VEGF165 versus vehicle ex vivo incubated E20
normoxic muscle bundles. ## P,0.01 versus VEGF165 ex vivo incubated E20 normoxic LV muscle bundles.
doi:10.1371/journal.pone.0005155.g006
Fetal Hypoxia & Cardiomyopathy
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Figure 7. Treatment of hypoxic chick embryos with sFlt-1. A to C, LV dilatation is absent in hypoxic chick embryos treated with sFlt-1 as
compared with normoxic (N) and hypoxic (H) controls. Scale bars represent 1 mm. D and E, M-mode echocardiography of normoxic and hypoxic
embryos showing that LV dilatation (arrows, yellow lines) is prevented by sFlt-1 treatment. F, treatment of hypoxic embryos with sFlt-1 restores the
LV ejection fraction. G, treatment of hypoxic embryos with sFlt-1 restores LV contractility as assessed in isolated muscle bundles. H, the time to 50%
relaxation at increasing calcium concentrations of isolated LV muscle bundles shows no difference between sFlt-1 treated and vehicle treated hypoxic
embryos, both n= 5. Data are shown as mean6SE; * P,0.05 sFlt-1 treated versus vehicle treated hypoxic embryos.
doi:10.1371/journal.pone.0005155.g007
Fetal Hypoxia & Cardiomyopathy
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The increased expression of large VEGF-A isoforms (VEGF166
and VEGF190) in hypoxic embryonic hearts provided us the
rationale for studying the role of this hypoxia-responsive cytokine.
We show in vivo that both conditions of increased and decreased
VEGF-A levels have an essential role in the origin of the cardiac
disease. First, exposing normoxic embryos to rhVEGF165 initiated
LV dilatation and loss of wall mass. Vice versa, scavenging VEGF-
A with sFlt-1 in hypoxic embryos prevented LV dilatation and loss
of wall mass, and restored LV ejection fraction and muscle bundle
contractility to levels resembling normoxic embryos. In contrast,
diastolic properties remained unchanged in E20 hypoxic embryos
after sFlt-1 treatment, suggesting separate mechanisms for systolic
and diastolic dysfunction. It has been reported that reduced
cardiac VEGF signaling interferes with myocardial angiogenesis,
resulting in local ischemia, which triggers cardiomyocyte damage
and heart failure [32]. In our experiments, we observed the
opposite effect; reducing cardiac VEGF levels with sFlt-1
prevented cardiac disease in hypoxic embryos. The number of
arterioles quantified in LV myocardium was similar in sFlt-1 and
vehicle-treated hypoxic embryos (data not shown), suggesting that
the effect of sFlt-1 was independent from the cardiac vasculature.
Both experiments in isolated LV muscle bundles and in
cardiomyocytes demonstrated that specifically the VEGF165
isoform exerts a negative inotropic effect. We found that chick
embryo cardiomyocytes express the VEGF receptors VEGFR-2
and NRP1. Exposure of LV muscle bundles to SU5416, a selective
inhibitor of VEGFR-2 signaling [17] or to Sema3A, a competitive
antagonist of VEGF165 binding to NRP1 [18] blocked the negative
inotropic effect of rhVEGF165. Taken together, our experiments
suggest that the large VEGF165 isoform, through binding to
VEGFR-2 and NRP1, directly affects the contractile properties of
cardiomyocytes, thereby initiating LV dilatation and cardiac
disease.
A recent study on intrauterine growth restriction in human
fetuses indicated that increases in cardiac afterload and end-
diastolic filling pressure were the most important effects on the
cardiovascular system. Also evidenced were disturbances in
arterial and cardiac compliance. These alterations may potentially
program the growth-retarded fetus for cardiac hypertrophy and
hypertension [33]. Aortic remodeling, sympathetic hyperinnerva-
tion, and alterations of vascular tone in hypoxic embryos [8–10]
may all contribute to increased cardiac afterload. In the present
study we identified VEGF as a trigger for cardiac disease in a
hypoxic chick embryo model. An afterload-independent effect of
VEGF in the development of cardiac disease is supported by the
finding that administration of VEGF to normoxic embryos, which
theoretically decreases cardiac afterload, also induced LV
dilatation and contractile dysfunction. Our in vitro experiments
suggest that elevated cardiac VEGF165 levels directly affect
cardiomyocyte function and warrant further research on the
specific mechanism.
Methods
Ethics Statement
All experiments were approved by the Institutional Animal Care
and Use Committee of the Maastricht University and complied
with the principles of laboratory animal care.
Animals
Fertile White Leghorn eggs were incubated at 21% O2
(normoxia; N) or 15% O2 (hypoxia; H) throughout embryonic
development as described previously [9,10]. Experiments were
performed between E10-E20 of the 21-day incubation period. To
evaluate the effects of embryonic hypoxia on the adult heart,
normoxic and hypoxic chick embryos were allowed to hatch at
E21 and both groups were raised under normal ambient oxygen
levels of 21% O2. Structural and functional analysis of adult hearts
was performed at 8 months after hatching. Chick embryos and
adult chickens were sacrificed by decapitation.
Cardiac histology
Hearts were fixed during diastole using 100 mmol/L CdCl2.
LV cross-sectional area was measured on formalin-fixed sections
(ImageJ, National Institutes of Health). Consecutive paraffin-
embedded 5-mm sections were stained with hematoxylin and eosin
(HE), PAS, and trichrome Masson to visualize tissue fibrosis. The
area of fibrotic tissue was quantified by computer software
(Quantimet 570, Leica). Ultrastructural analysis of epoxy resin
embedded hearts was performed on 70-nm sections.
Titin protein levels
Hearts from normoxic and hypoxic E20 embryos were excised,
snap-frozen, and stored at 280uC. Left ventricular tissue samples
were homogenized in 4 mL SET-buffer (in mol/L 0.25 sucrose,
0.01 Tris-HCl, 0.002 Na2-EDTA; pH 7.4). Leupeptin (0.5 mmol/
L) was added to prevent protein degradation. Protein content was
determined by the Micro BCA method (Pierce, Rockford, USA).
Samples (20 mg protein) were loaded on a 2% SDS-polyacryl-
amide slab gel reinforced with agarose and electrophorized using a
Mini-PROTEAN II electrophoresis system (BioRad, Hercules,
USA). Fairbanks running buffer was used for electrophoresis and
the conditions were 7.5 mA/gel for 30 min and 15 mA/gel for
5 hours [34]. Gels were stained with Coomassie Brilliant Blue R-
250. The integrated optical density (OD) of N2BA titin, N2B titin,
total titin (N2BA+N2B), and myosin heavy chain (MHC) were
determined at each lane.
Embryonic echocardiography
Echocardiography was performed in vivo at E20. The animals
were carefully hatched with as less blood loss as possible and
immediately investigated. Heart rates and temperatures were
monitored (Model THM100, Indus Instruments, Houston, Texas),
and heating was adjusted to maintain a body temperature between
36 and 38uC. All feathers were removed from the abdomen by
gentle shaving. Pre-warmed gel was applied to the precordium as
an ultrasound coupling medium (Parker Laboratory, Orange, NJ).
Chick embryo hearts were imaged transcutaneously using the
ultrasound biomicroscope (UBM) and a 30 MHz or 40 MHz
transducer operating at 30 frames/s (Model Vevo 660, VisualSo-
nics Inc., Toronto, Canada). Generally, the heart was first imaged
in the two-dimensional (2-D) mode in the short-axis view. Images
from this view were used to measure left ventricular (LV) cross-
sectional area. Images were stored on harddisk for review and
analysis. LV end-diastolic diameter (LVEDD) was measured from
the M-mode tracings of the maximum chamber cavity. All
measurements were performed from leading edge to leading edge
according to the American Society of Echocardiography guide-
lines. Ejection fraction was calculated from the LV cross-sectional
area (2-D short-axis view) using the equation EF
(%) = [(LVDA2LVSA)/LVDA]6100; where LVDA is LV dia-
stolic area and LVSA is LV systolic area. All primary
measurements such as LV wall thickness, dimensions, and cross-
sectional areas were traced manually and digitized by goal-
directed, diagnostically driven software installed within the
echocardiograph. Three beats were averaged for each measure-
ment.
Fetal Hypoxia & Cardiomyopathy
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Isolated LV muscle bundles
Hearts were in situ perfused with 0.2 mL heparin (5000 U/
mL), and immediately after surgical resection placed in a Ca2+-
free solution (in mmol/L: 135 NaCl, 5.4 KCl, 0.33 NaH2PO4,
10 HEPES, 10 C6H12O6xH2O, 1 MgCl2, and 30 2,3-
Butanedione 2-monoxime, pH 7.4, gassed with 100% O2). A
thin subendocardial LV muscle bundle was excised in parallel
with fiber direction, mounted in an organ bath with HEPES
buffer (in mmol/L: 10 HEPES, 2 Ca2+, pH 7.4, gassed with
100% O2, 37uC) between a rigid hook and a force transducer
connected to a micromanipulator for length adjustment, as
described [10,35].
After an equilibration period of 10 minutes, the muscle bundle
was paced by external field stimulation with rectangular pulses
(5 ms, 5% to 10% above threshold) at a frequency of 1 Hz. This
resulted in isometric contraction of the fiber. Subsequently, the
muscle was stretched in steps of 218 mm. Passive tension (mN)
was determined by measuring force during diastole, i.e.
unstimulated force, at incremental bundle lengths [36]. The
length-active tension relation, i.e. Frank-Starling relation, was
assessed by measuring active force generation during field
stimulation at incremental bundle lengths. Bundle length was
expressed as a percentage of Lmax. Generated force was defined
as peak systolic minus diastolic force and normalized to cross-
sectional area (mN/mm2) by optical measurement of the smallest
diameter of the bundle assuming cylindrical geometry. Muscle
bundles were stretched until the fiber length was reached which
provided maximal active force generation (100% Lmax). For
standardization purposes, all further experiments were per-
formed at 100% Lmax after a resting period of 5 minutes.
Isometric contractile force development was measured in
response to increasing extracellular calcium (2–12 mmol/L).
Relaxation properties of the LV muscle bundles were assessed by
measuring the time to 50% relaxation during diastole in these
experiments.
VEGF and cardiac performance
In separate experiments, contractility of LV muscle
bundles from normoxic E20 chick embryos was measured after
4 hours incubation with: 100 ng/mL rhVEGF165 [37], 600 ng/
mL rhVEGF121 [37], 600 ng/mL placental growth factor-1
(rhPlGF-1), 100 ng/mL rhVEGF165+130 ng/mL sFlt-1, 100 ng/
mL rhVEGF165+130 ng/mL rhSema3A (all R&D Systems),
100 ng/mL rhVEGF165+50 mmol/L SU5416 (Sigma), or HEPES
buffer alone.
The effect of VEGF was further defined in vitro by measuring
fractional shortening of isolated rat cardiomyocytes in response to
rhVEGF165 or rhPlGF-1 (500 ng/mL) using a Ionoptix Contrac-
tility System (Ionoptix, Milton, MA, USA) [38].
Molecular analysis
Real-time PCR for atrial natriuretic factor (ANF), VEGF,
VEGFR-2, and NRP1 was conducted using the My iQ iCycler
and iQ SYBR Green Supermix (both Bio-Rad) (Table 2). Semi-
quantitative PCR analysis was performed to detect the expression
of VEGF-A mRNA splice variant isoforms [39]. Cardiomyocyte
apoptosis was assessed by in vivo molecular imaging using annexin-
V [40].
In vivo application of VEGF165 or sFlt-1
To test the involvement of VEGF165 in hypoxia-induced LV
dilatation, normoxic chick embryos received a daily systemic dose
of rhVEGF165 (R&D Systems, 50 or 100 ng/day) between E10
and E19. Vice versa, hypoxic embryos were treated with sFlt-1
(both R&D Systems, 13 ng/day) between E10 and E19 [41].
Controls received saline. The solutions were administered by daily
0.1 mL bolus injections in the air space of the egg [42]. Cardiac
morphology and function were analyzed at E20.
Data analysis
Data are expressed as mean6SE. The term n refers to the
number of animals. Multiple comparisons were made using the
non-parametric Mann-Whitney U test. Statistical significance was
defined as P,0.05.
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